Zefiro Methane dispute heads to BCSC hearing

Executive Summary

• Dr. Talal Debs, founder and former chairman of Zefiro Methane Corp., along with concerned shareholders X Machina Capital Strategies (XMC) and X Machina Sustainable Technologies Inc. (XMST), are petitioning the British Columbia Securities Commission (BCSC) to intervene against alleged "entrenchment tactics" by the current board of directors.
• The core of the complaint involves the issuance of 13,214,494 debt settlement shares one day before the record date for the upcoming Annual General and Special Meeting (scheduled for March 4, 2026). The concerned shareholders argue these shares were issued to "friendly hands" to dilute their voting power and influence the outcome of a proxy contest.
• The hearing is tentatively scheduled for February 25, March 3, and March 4, 2026. The shareholders are seeking remedies such as rescinding the share issuance or preventing the new shares from voting.

Key Details

• BCSC Hearing Dates: Tentatively scheduled for Feb. 25, March 3, and March 4, 2026.
• Shareholder Holdings: XMC and XMST collectively held 27.5% of common shares prior to recent dilutions. Dr. Debs beneficially owns or controls 20,914,750 common shares (23.12% of issued and outstanding), though he does not intend to vote 500,000 personal shares.
• Alleged Entrenchment via Share Issuance:
  • The company issued 13,214,494 shares for debt settlement one day prior to the record date for the AGM.
  • Recipients include Zefiro director and interim CEO Catherine Flax, David McGrath (counterparty in litigation against Dr. Debs), and Michael McGavick (co-chairman of Bridgewater Associates).
  • These recipients collectively received 14.6% of issued and outstanding shares, which the shareholders argue is enough to decide the proxy vote.
  • The debt was not due for 10 months, and the issuance included payment for unaccrued interest despite no obligation to pay interest once principal was paid.
• Requested Remedies:
  • Rescind the issuance of the debt settlement shares.
  • Alternatively, prevent the newly issued shares from being voted at the meeting.
• Additional Alleged Tactics:
  • Removal of Dr. Debs from CEO and Chair roles and initiation of a costly investigation against him.
  • Amendment of employment agreements to include off-market change of control bonuses for Ms. Flax and other executives.
  • Previous issuance of 1,127,273 shares and 400,000 options in November 2025 for debt settlement.
  • Unprecedented amendment to the advance notice policy, granting the board discretionary authority to disqualify director nominees.
  • Breach and invalidation of an investor rights agreement held by XMST.
  • Failure to call the annual general meeting on a timely basis.
• Meeting Schedule: The AGM and Special Meeting are currently scheduled for March 4, 2026. Dr. Debs expects the company to postpone the meeting to March 31, 2026, to allow time for the BCSC decision.
• Solicitation Status: Dr. Debs is not currently soliciting proxies but may file a dissident information circular. Costs for solicitation are borne by XMC.

Notable Quotes

• "The board of directors expects shareholders to believe it was a coincidence that they decided to put 13.2 million newly issued shares into friendly hands one day before the deadline for participating in the proxy contest. They make accusations of inappropriate behaviour despite consistently showing a willingness to dilute shareholders, failing to adhere to accepted corporate governance standards and spending the company's limited cash for the purpose of entrenching and enriching themselves." — Dr. Talal Debs